Cerity Partners
CRNX icon

Cerity Partners’s Crinetics Pharmaceuticals CRNX Stock Holding History

Cerity Partners’s Portfolio CRNX Stock Details CRNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$747K Buy
20,576
+1,602
+8% +$71.6K ﹤0.01% 2035
2025
Q4 		$883K Buy
+18,974
New +$845K ﹤0.01% 1775

Other funds holding CRNX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

Cerity Partners's CRNX Position: Q1 2026 in Review

Cerity Partners increased its Crinetics Pharmaceuticals (CRNX) stake by 8.4% in Q1 2026, buying an estimated $71.6K and bringing the position to 20,576 shares worth $747K. The position accounts for ﹤0.01% of the portfolio, ranked #2035.

Cerity Partners first reported a position in CRNX in Q4 2025 and has held it in 2 quarters since. The position peaked at $883K in Q4 2025. 243 funds tracked by Wall St. Rank hold CRNX as of Q1 2026.

  • Cerity Partners held 20,576 shares of Crinetics Pharmaceuticals worth $747K as of Q1 2026.
  • Cerity Partners bought 1,602 Crinetics Pharmaceuticals shares in Q1 2026, an estimated $71.6K.
  • Crinetics Pharmaceuticals made up ﹤0.01% of Cerity Partners's portfolio in Q1 2026, its #2035 holding.
  • Cerity Partners first reported a position in Crinetics Pharmaceuticals in Q4 2025 and has held it in 2 quarters since.
  • Cerity Partners's Crinetics Pharmaceuticals position peaked at $883K in Q4 2025.
  • 243 funds tracked by Wall St. Rank held Crinetics Pharmaceuticals as of Q1 2026.

Based on Cerity Partners's 13F filing for Q1 2026, filed 15 May 2026.